[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lifestyle-modification\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lifestyle-modification":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,47,86,122,152,187],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100627540","effect-of-counselling-using-lifestyle-medicine-assessment-tool-on-hypertensive-patients-100627540",false,"NCT07449962","Effect of Counselling Using Lifestyle Medicine Assessment Tool on Hypertensive Patients","Effect of Counselling of Patients With Hypertension Presenting in Family Medicine Clinics Using Lifestyle Medicine Assessment Tool.","Inclusion Criteria:\n\n1. Adult patients aged 18-65 yrs with diagnosed primary\u002Fessential hypertension, defined as two or more clinic BP readings of ≥130\u002F80 (ACC\u002FAHA Guidelines).\n2. If taking anti hypertensives, then on a stable regime i.e. no recent medication change for at least ≥4 weeks.\n3. Willing and able to participate in the study.\n\nExclusion Criteria:\n\n1. Diagnosed secondary hypertension.\n2. Moderate to severe CKD (eGFR \\\u003C60 ml\u002Fmin\u002F1.73m2).\n3. Moderate to severe ischemic heart disease.\n4. Diabetes Mellitus requiring insulin.\n5. Major psychiatric disorder such as dementia or schizophrenia.\n6. Pregnancy or Lactating mother.\n7. Unable to participate in study\u002F Severe mobility limitation.","ALL","18 Years","65 Years",{"count":20,"type":21},64,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn if knowing and understanding a patient's daily habits and then giving clear advice on what changes to make can help control blood pressure better than the routine way of advising people with high blood pressure. The main questions it aims to answer are:\n\n* To learn if using the Lifestyle Medicine Assessment tool (A 21-item questionnaire) to understand the current lifestyle of people with hypertension and guide them accordingly, helps in lowering blood pressure more, as compared to routine advice?\n* To see if this way of guiding patients is more satisfactory for them then routine advice? Researchers will compare two groups of people with hypertension. One will be guided after assessing their current lifestyle with the Lifestyle Medicine Assessment Tool and one will be given routine guidance. The researchers will then see which group had better blood pressure control.\n\nParticipants will be:\n\n* Asked a few questions about their lifestyle and then they will be advised accordingly on ways to make it better.\n* They will also be asked to measure their blood pressure at home and bring the record with them when they come for their doctor's visit.",[27,28,29,30],"Lifestyle Intervention","Lifestyle Modification","Hypertension","Counselling",[32,33],"lifestyle counselling of hypertensive patients","Lifestyle Medicine Assessment Tool","NOT_YET_RECRUITING","2026-04-25",{"date":37,"type":38},"2026-04-30","ACTUAL",{"date":40,"type":21},"2026-06",{"date":42,"type":21},"2027-02",{"name":44,"class":45},"Indus Hospital and Health Network","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":67,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":46},"100585558","phase-2-bone-metabolism-in-12-21-year-olds-undergoing-glucagon-like-peptide-glp-1-receptor-agonist-therapy-100585558","NCT06903923","Bone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist Therapy","Bone Metabolism in Adolescents Undergoing GLP-1 Receptor Agonist Therapy","Inclusion Criteria:\n\n* • Adolescents and young adults with obesity 12-21 years old starting GLP-1 RA therapy (except for dulaglutide or exenatide) or followed with 'usual' care.\n* Diagnosis of obesity (BMI ≥ 95th percentile for age and sex). The FDA has approved the use of GLP-1 RAs (liraglutide and semaglutide) for adolescents ≥ 12 years old with BMI ≥ 95th percentile for age and sex, and tirzepatide for adults with obesity. Those in the GLP-1 RA arm must have demonstrated efforts at weight loss with 'usual' care, and consistent compliance with appointments and recommendations.\n* Participants must demonstrate sufficient maturity, psychological stability and cognitive capacity to recognize the significance of being on medical therapy and implement required behavioral changes\n* Patients taking orlistat as a precursor to GLP-1 RA therapy due to insurance requirements may be included given minimal effects on weight.\n* Use of the following contraceptive methods is permitted: Combine oral contraceptives (COCs); continuous oral progestin; Progestin-releasing intrauterine device (IUD); Progestin implant; transdermal patch.\n* Patients with celiac disease will be included if the condition is well controlled and they are on a gluten free diet with normal 25(OH)D levels confirmed by clinical labs within 3 months of enrollment in the study. If a patient does not have recent 25(OH)D results, we will add this to the screening labs.\n\nExclusion Criteria:\n\n* • Current or previous history of pregnancy and breast feeding.\n* Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 if in the GLP-1 RA group.\n* \\> 5 kg weight loss over 3 months given the known impact of significant weight loss on bone density.\n* Use of dulaglutide and exenatide (of the GLP-1 RAs) given minimal weight loss with these drugs.\n* Use of medications such as metformin, phentermine, or topiramate that may cause weight loss, or obesogenic antipsychotic medications if treated for \\\u003C3 months, or if dosage is not stable for \\>2 months.\n* Medications other than calcium or vitamin D that affect bone, such as systemic glucocorticoids, phenytoin, phenobarbitone (unless there is a washout period of 3 months prior to enrollment if discontinuation is medically permissible)\n* Female participants on hormonal contraception will be excluded if this involves use of depot medroxyprogesterone acetate (DMPA). DMPA has profound deleterious effect on bone density, which could confound study outcomes related to bone health. Rationale: DMPA has a well-documented deleterious effect on bone density, which could confound study outcomes related to bone health or metabolic parameters.\n* Untreated thyroid dysfunction or on stable dose for \\\u003C3 months. Primary thyroid dysfunction will be defined as: a TSH ≥ 10 IU\u002FL or low per given reference range with unknown thyroid antibody status, or an abnormal TSH if known positive antibodies. Patients with known hypothyroidism will be included if appropriately treated with levothyroxine and have a normal TSH. For patients with secondary hypothyroidism (deficient production of TSH from the pituitary gland causing hypothyroidism), normal free T4 concentrations (and not TSH alterations) will be used for study inclusion, and recent adjustments in the levothyroxine dose will be permissible as long as free T4 concentrations are in the normal range at dose adjustment (as dose adjustments are often made to get free T4 concentrations in the upper half of the normal range when assessed levels are in the lower half of the normal range). Patients with hyperthyroidism will be excluded given known deleterious effects on both weight and bone metabolism.\n* Medical conditions known to impact weight or bone density, such as chronic gastrointestinal disorders (including inflammatory bowel disease), other inflammatory conditions, such as rheumatoid arthritis or ankylosing spondylitis, untreated thyroid disease, and hypercortisolemia.\n* HbA1C \\>8% (to avoid deleterious effects on bone from uncontrolled T2DM).\n* Smoking \\>10 cigarettes\u002Fday given deleterious effects on bone; substance abuse per DSM-5.\n* Weight \\>450 lbs due to limits for DXA scanners.\n* History of metabolic and bariatric surgery.\n* Judged by the investigators to be inappropriate for the study for other reasons not detailed above.","12 Years","21 Years",{"count":57,"type":21},120,[59],"PHASE2","The goal of this clinical trial is to compare bone health markers over 24 months in participants 12 - 21 years of age with obesity who are starting the glucagon-like peptide-1 receptor agonists (GLP-1RAs) as compared to those with similar weight followed by lifestyle management.\n\nParticipants will:\n\n* Take GLP-1RA as prescribed or continue to work on lifestyle management for weight loss\n* Take provided calcium and vitamin D supplements\n* Attend 6 study visits over 24 months with two at the beginning and then every 6 months that include:\n\n  * History and Physical Exams\n  * Lab Work\n  * Imaging studies\n  * Questionnaires\n  * 24-hour dietary recalls",[62,63,64,28,65,66],"Obesity in Children","Bone Strength","GLP - 1","Bone Density","Obesity",[68,69,70,71,72,73,74,75],"obesity","obesity in children","bone strength","GLP-1","Lifestyle modification","bone density","semaglutide","liraglutide","RECRUITING","2026-04-15",{"date":79,"type":38},"2026-04-17",{"date":81,"type":38},"2025-07-31",{"date":83,"type":21},"2030-04-30",{"name":85,"class":45},"University of Virginia",{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":94,"sex":16,"minAge":95,"maxAge":96,"enrollmentInfo":97,"targetDuration":4,"studyType":22,"phases":99,"briefSummary":100,"conditions":101,"keywords":104,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":121},"100613351","a-family-centred-approach-enhancing-cardiovascular-health-in-ugandan-adolescents-and-their-families-100613351","NCT07265453","A Family-centred Approach Enhancing Cardiovascular Health in Ugandan Adolescents and Their Families","A Family Centred Approach to Enhance Lifestyle Change and Behavioural Modification for Prevention of Cardiovascular Diseases Among Adolescents and Their Families in Uganda","FaCe-D","Inclusion Criteria:\n\n* Aged 10 -19 years\n* Household head\u002Fparent has provided consent\u002Fpermission\n* Planning to continue staying in the study village for the next 12 months\n\nExclusion Criteria:\n\n* In a boarding school or planning to join a boarding school\n* Pregnant or lactating\n* Known to have a chronic condition such as mental illness\n* The adolescent does not assent or consent",true,"10 Years","19 Years",{"count":98,"type":21},1280,[24],"The FaCe-D Study, with funding from the Canadian Institute for Health Research (CIHR) through Global Alliance for Chronic Diseases (GACD) aims to adapt and implement an evidence-based family centred approach (FCA) to prevent cardiovascular diseases (CVD) among adolescents and their families. This 5-year implementation science study will be conducted in 16 villages in Jinja district and another 16 in Kampala beginning April 2024 to evaluate the effectiveness of FCA in reducing the risk of CVD in Uganda and to assess feasibility, adoption, while measuring the costs of implementation. The study will be implemented by a group of researchers from MRC\u002FUVRI \\& LSHTM, University of British Columbia (Canada), TASO (Uganda) and University of California San Francisco (UCSF) - USA with guidance from the Ministry of Health - Uganda.",[102,28,103],"Adolescent Behavior","Cardiovascular Disease Other",[105,106,107,108,109,110,111],"cardiovascular risk","CVD","Ideal cardiovascular health","physical activity diary","food diary","diet diary","family centered","2025-12-04",{"date":114,"type":38},"2025-12-12",{"date":116,"type":38},"2025-07-05",{"date":118,"type":21},"2028-01",{"name":120,"class":45},"MRC\u002FUVRI and LSHTM Uganda Research Unit",2,{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":22,"phases":131,"briefSummary":132,"conditions":133,"keywords":136,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":46},"100507940","impact-of-a-diabetes-education-mobile-web-application-on-patients-with-uncontrolled-type-2-diabetes-100507940","NCT05893927","Impact of a Diabetes Education Mobile Web Application on Patients With Uncontrolled Type 2 Diabetes","Evaluating the Clinical Impact of a PCP Developed Diabetes Education Mobile Web Application on Patients With Uncontrolled Type 2 Diabetes","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of Type 2 Diabetes with HA1c \\>8.0\n* Current patients of the Family Healthcare Center, Reading Hospital Tower health.\n\nExclusion Criteria:\n\n* Identified special populations (pregnancy or individuals currently incarcerated)\n* Patients without access to their own smart phone\n* Any patient who is unable to provide their own informed consent to participate in the study",{"count":130,"type":21},65,[24],"The goal of this clinical trial is to evaluate the use and effectiveness of a mobile web application (app) that is designed to educate and allow patients to manage diabetes and make sustainable lifestyle changes, and to study the impact of the app on clinical outcomes of diabetes (HA1C) and educational outcomes (Self-Efficacy for Diabetes Scale). The main question to answer is: Does the use of the Diabetes Application significantly affect clinical outcomes of diabetes and cardiometabolic risk factors (BMI and Blood Pressure)? Patients will be enrolled in one of two available arms of the study.\n\nParticipants in the 'intervention arm' will use the app to view educational information presented as videos in the following areas: Healthy Coping, Healthy Eating, Staying Active, Medications (Use and Safety), Problem Solving in Diabetes and Disease Pathophysiology. They will continue routine follow-up care with their primary care physicians during the study.\n\nParticipants in the 'control arm' will continue with their primary care physician in routine follow-up care, as normally scheduled.\n\nResearchers will compare the intervention arm participants to the control arm participants to find out about and compare changes in HA1C, systolic blood pressure, diastolic blood pressure, and body mass index. Groups will also be compared on the basis of self-perceived confidence of managing their diabetes by way of the Diabetes Self Efficacy Scale.",[134,135,28],"Diabetes Mellitus, Type 2","Diabetes Education",[137,138,139,140,141,142],"Type 2 diabetes","Type II diabetes","uncontrolled type 2 diabetes","hyperglycemia","mobile web application","Diabetes education","2025-07-25",{"date":145,"type":38},"2025-07-30",{"date":147,"type":38},"2024-02-15",{"date":149,"type":21},"2026-09-30",{"name":151,"class":45},"The Reading Hospital and Medical Center",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":16,"minAge":160,"maxAge":161,"enrollmentInfo":162,"targetDuration":4,"studyType":22,"phases":164,"briefSummary":165,"conditions":166,"keywords":174,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":46},"100585834","preventative-screening-and-health-coaching-in-a-food-insecure-population-100585834","NCT06907524","Preventative Screening and Health Coaching in a Food Insecure Population","Community-Based Preventative Cardiometabolic Screening and Health Coaching- A Prospective Study","HEALTHCOACH","Inclusion:\n\nPatient is a participant at a CHI sponsored, community screening event Patient provides informed consent and willingness to participate for the duration of the study English or Spanish speaking Age 40-75 years old At least 1 cardiometabolic risk factor at suboptimal level\n\nDefined as one or more of the following at initial screening:\n\nBlood Pressure (BP):\n\nSystolic BP greater than 130mmHg and\u002For diastolic BP greater than 80mmHg. Obesity: body mass index (BMI) greater than 30 〖kg\u002Fm〗\\^2\n\nDyslipidemia:\n\nTotal cholesterol greater than 200 mg\u002FdL Triglycerides greater than 150 mg\u002FdL Low density lipoprotein (LDL) greater than 130 mg\u002FdL High density lipoprotein (HDL) less than 40 mg\u002FdL in men or less than 50 mg\u002FdL in women Hemoglobin A1c greater than or equal to 5.7% 10-year ASCVD score greater than 5% Access to a telehealth compatible device\n\nExclusion:\n\nAdults unable to provide informed consent or unwilling to participate for study duration Speaks language other than English or Spanish Younger than 40 years old or older than 75 years old All cardiometabolic risk factors at optimal levels No telehealth compatible device Pregnant patients","40 Years","75 Years",{"count":163,"type":21},200,[24],"The goal of this longitudinal study is to investigate the role of virtual health coaching on mitigation of cardiometabolic disease risk in an underserved, food insecure population. The main questions it aims to answer are:\n\n* Does longitudinal, individualized health coaching directed at lifestyle modification reduce patient 10-year risk of heart attack or stroke?\n* Does longitudinal, individualized health coaching directed at lifestyle modification reduce rates of hypertension, hyperlipidemia, and diabetes?\n* Does longitudinal, individualized health coaching directed at lifestyle modification improve accessibility to healthcare?\n\nResearchers will investigate the effects of regularly scheduled health coaching sessions on composite cardiometabolic risk profile as well as individual modifiable cardiovascular risk factors.\n\nParticipants will:\n\n* Participate in in-person cardiovascular screening, occuring at the time of enrollment, months 3 and 6.\n* Engage in virtual health coaching sessions to talk about diet, exercise, weight loss, blood pressure and diabetes control, and accessibility to healthcare\n* Keep a log of their blood pressure",[167,168,169,170,29,171,172,28,173],"Cardiovascular Disease Prevention","Cardiometabolic Diseases","Cardiovascular Risk Factor","Cardiovascular Risk Score","Hyperlipidemia","Diabetes","Health Coaching",[167,175,29,171,172,28,173,170,176,169,177],"Cardiometabolic Disease Screening","Atherosclerotic Cardiovascular Disease Risk Score","Cardiometabolic Disease","2025-03-26",{"date":180,"type":38},"2025-04-02",{"date":182,"type":21},"2025-04-01",{"date":184,"type":21},"2027-07-01",{"name":186,"class":45},"Rush University Medical Center",{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":94,"sex":16,"minAge":194,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":22,"phases":197,"briefSummary":198,"conditions":199,"keywords":200,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":46},"100524769","keystepsjc-phase-two-study-100524769","NCT06113042","KeySteps@JC Phase Two Study","Effectiveness and Sustainability of a Community Child Health Model in Community Settings","Inclusion Criteria:\n\n1. Children are studying in kindergartens which agree to join the project.\n2. Parent\u002Flegal guardian of the child consented the child's participation in to the study.\n3. Participants of the Lifestyle modification Programme should be K1 students in academic year 2023\u002F24 of the selected kindergartens and their parents\u002Fguardians.\n\nExclusion Criteria:\n\n1. Parent\u002Flegal guardian of the child cannot understand Cantonese.\n2. Parent\u002Flegal guardian of the child cannot read Chinese.","3 Years",{"count":196,"type":21},6000,[24],"This proposed 'KeySteps Phase Two Study' is a 5-year study, which aims to investigate the effectiveness and sustainability of a Community Child Health Model with different services related to healthy lifestyle programmes and health promotion implemented in community settings of deprived living areas. Potential participants are children studying or living in the five selected districts, namely Sham Shui Po, Yuen Long, Tuen Mun, Sha Tin and Kowloon City. Data including children's health and psychosocial conditions, and family demographics will be collected. In addition, subjects will receive on-site assessments on general health and development. Medical and health related events of subjects will be tracked through the existing health care system. Subjects will receive health promotion services and\u002For lifestyle modification programmes according to their needs.",[28],[201,202,203,204,205,206,72,207],"Community child health","Child development","Nutrition","Physical activity","Sleep","Healthy lifestyle","KeySteps","2023-12-22",{"date":210,"type":38},"2023-12-26",{"date":212,"type":38},"2023-11-01",{"date":214,"type":21},"2028-12-31",{"name":216,"class":45},"The University of Hong Kong"]